Global radiopharmaceuticals/nuclear medicine market report gives a comprehensive outlook on radiopharmaceuticals across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). The report on radiopharmaceuticals/nuclear medicine market gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application area, route of administration, end user, and geographic regions. This report studies radiopharmaceuticals//nuclear medicine market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, radiopharmaceuticals/nuclear medicine market report includes new product introductions; regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition.
A sample of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/#ulp-4H8Z4LpNMLEuOnnx[/URL]
Radiopharmaceuticals market estimated to be valued US$ 5,146 Mn in 2017 and poised to grow at CAGR of 8.9% over 2017-2023. The market for radiopharmaceuticals projected to reach US$ 8,564 Mn by 2023 owing to increasing adoption in radiotherapeutic and diagnostic procedures across the globe.
Development of effective radiopharmaceuticals for diagnosis and treatment expected to drive the market revenue growth over the forecast period. The advances in imaging devices with radio-activity are aiding healthcare professionals in effective diagnosis. Moreover, radio-imaging diagnosis is considered as an effective alternative to the conventional diagnosis techniques such as X-rays which expected to boost the market demand for diagnostic radiopharmaceuticals across the globe. In addition, increase in the healthcare expenditure, radiopharmaceuticals abundance, and non-invasiveness in the treatment and diagnostic procedure might bolster the nuclear medicine market over the forecast period.
To view TOC of this report is available upon request @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/#ulp-c654SbFYO64MsOhu[/URL]
North America market holds the higher revenue share in global radiopharmaceuticals market and projected to remain same over the forecast period owing to rising FDA approvals and production of radiopharmaceuticals in the region. Asia-pacific radiopharmaceuticals market projected to grow at significant CAGR over the forecast period in comparison with other regions owing to conducive business environment and rising PET installations in the region
Competition Assessment
Key players profiled in the global Radiopharmaceuticals market include:
• Advanced Accelerator Applications S.A. (France)
• Bayer AG (Germany)
• Bracco Imaging S.p.A (Italy)
• Cardinal Health, Inc. (U.S.)
• Eli Lilly and Co. (U.S.)
• GE Healthcare (U.S.)
• IBA Molecular Imaging (Belgium)
• Jubilant Life Sciences Ltd (India)
• Lantheus Medical Imaging, Inc. (U.S.)
• Mallinckrodt plc (Ireland)
• Navidea Biopharmaceutical (U.S.)
• Nordion, Inc. (Canada)
• Siemens Healthineers (Germany)
Need more information about this report @
[URL]https://www.precisionbusinessinsights.com/market-reports/global-radiopharmaceuticals-nuclear-medicine-market/[/URL]